Floatz logo

Nk Cell

NK Cell

Peking University First HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the NK Cell cohort.

Asset / SponsorPhaseRating
Autologous Nk Cell
Xiangyang No.1 People's Hospital
Phase 1/2CC
Donor-Derived Cd123-Cd16 Bispecific Antibody-Modified Nk Cells
Chunji Gao
Phase 1CC
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Nk Cell is also rated in:

acute myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →